Clinical Trials Logo

Myasthenia Gravis clinical trials

View clinical trials related to Myasthenia Gravis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04982289 Withdrawn - Clinical trials for Generalized Myasthenia Gravis

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (PD), immunogenicity, and efficacy of subcutaneous (SC) ALXN1830 in adults with generalized myasthenia gravis (gMG).

NCT ID: NCT04541875 Withdrawn - Cystic Fibrosis Clinical Trials

Medication Adherence and Non-adherence in Adults With Rare Disease

Start date: January 2021
Phase:
Study type: Observational

The purpose of this study is to use the Medication Adherence Reasons Scale (MAR-Scale) to determine the extent of non-adherence to specific medications indicated to treat cystic fibrosis, hemophilia (A or B), idiopathic pulmonary fibrosis, myasthenia gravis, and sickle cell disease, and to identify the top patient-reported reasons for non-adherence. Internal reliability of the MAR-Scale will also be assessed in each condition.

NCT ID: NCT03900585 Withdrawn - Myasthenia Gravis Clinical Trials

Can Interval Walking Influence on Fatigue in the Danish Cohort of Myasthenia Gravis Patients

Start date: August 2019
Phase: N/A
Study type: Interventional

The study is a controlled, randomized intervention trial. Patients are randomized into either an intervention group or a control group. The duration of the study is 10 weeks. Patients in the intervention group participate in a 10 weeks exercise program consisting of 150 minutes interval walking per week administered by an app on the patient's telephone. Patients in the control group live as usually, with a maximum of 30 minutes aerobic exercise per week. Before and after the 10 weeks study period, patients (from both the intervention and the control group) participate in a 2 hours session of functional testing (e.g. walk tests, test of muscle strength ect.) at Rigshospitalet.

NCT ID: NCT03165435 Withdrawn - Clinical trials for Myasthenia Gravis, Generalized

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

Start date: July 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Study CV-0003 will be the second clinical trial administering CV-MG01 in humans. This will be a phase 2/3 proof-of-efficacy therapeutic confirmatory study following the proof-of-concept exploratory phase 1 study (CV-0002).